Death may be the most uncanny topic to discuss for human beings. Even thinking about it is uncomfortable for some people.
To eliminate the mystery behind it, researchers worldwide are conducting scientific studies on death and coming up with surprising results, such as when researchers captured brainwaves during an individual’s death and found semblance to high cognition activities.
And now, a team of scientists from the U.S. may have found a way to revive a glimmer of activity in human eyes after death. According to a study published yesterday (May 11, 2022) in the journal Nature, the team has managed to revive the connections between light-sensing neurons in organ donor eyes.
Israeli scientists say they have opened a possible new path to fighting infertility, by identifying a mechanism that seems to harm eggs when it malfunctions.
In peer-reviewed research published on Thursday in the journal Science, a team of Hebrew University researchers outline a mechanism they identified in studies of zebrafish and mice.
They say it plays a key role in ensuring that chromosomes inside eggs are organized correctly, so that they can be fertilized and produce healthy offspring.
Here at Lifespan.io, we publish fact-checked news and deep interviews with aging researchers to help people track the development of treatments targeting aging. These treatments aim at preventing and curing age-related diseases and may improve lives of thousands of people around the globe!
Everyone deserves to know about the emerging opportunities in the field of healthy life extension research. Knowledge is empowering. In our articles and popular science videos, we discuss the progress, pros, cons, and social implications of innovative medicine for controlling aging, and the steps that are needed to accelerate its clinical implementation.
How your giving made a difference in 6 years
Research on aging and life extension can allow people to be healthier for longer, and with your help, we can reach out to more people! Please consider supporting our work with a monthly donation!
Heart attacks are the world’s leading cause of death, yet the few treatments available are often expensive and inaccessible. Although that’s been the case for years, the World Health Organization warned back in 2020 heart disease numbers were still on the rise.
Verve Therapeutics says altering human genomes to prevent the buildup of bad cholesterol might be the answer, and is creating what CEO Sekar Kathiresan says may be a permanent solution to heart disease. The company is backed by Google Ventures, according to a report about the breakthrough published Friday inBloomberg. Verve also counts a Harvard medical professor and an award-winning medical expert among its cofounders.
“We’re on the cusp of potentially transforming that model to a one-and-done treatment,” Kathiresan told the business publication.
The human cytomegalovirus (CMV) is widely known as an endemic virus that, while usually asymptomatic, is known to cause with harmful effects in babies and older adults. However, some of its properties make this virus suitable for delivering gene therapies. As cytomegaloviruses can carry large genetic payloads and don’t overwrite the DNA of their host cells [1], replacing the genes of these viruses with beneficial DNA may be safer than approaches with more potential off-target effects; development in this area is ongoing, and a phase 1 human clinical trial has already been conducted [2].
R&D & Innovation For U.S. Security & Resilience — Kathryn Coulter Mitchell, Acting Under Secretary for Science and Technology, DHS Science and Technology Directorate, Department of Homeland Security.
Kathryn Coulter Mitchell (https://www.dhs.gov/person/kathryn-coulter-mitchell), is Acting Under Secretary for Science and Technology (S&T), at the U.S. Department of Homeland Security, where as the science advisor to the Homeland Security Secretary, she heads the research, development, innovation and testing and evaluation activities in support of the Department of Homeland Security’s (DHS) operational Components and first responders across the nation.
The Science and Technology Directorate is responsible for identifying operational gaps, conceptualizing art-of-the-possible solutions, and delivering operational results that improve the security and resilience of the nation.
In her former role as the Chief of Staff, Ms. Coulter Mitchell oversaw the operational and organizational needs of the $1 billion, 500-career-employee Directorate. A member of the Senior Executive Service, she was responsible for strategy, policy, organizational development, communications, and planning and she guided the creation of a DHS strategic vision and roadmap for research and development (R&D), the reestablishment of Integrated Product Teams to prioritize and manage DHS R&D investments, and the crafting of strategies for organizational effectiveness. Ms. Mitchell previously served S&T as Deputy Chief of Staff and Senior Communications Advisor for the Under Secretary and Deputy Under Secretary.
Ms. Coulter Mitchell came to DHS after a 15-year career in the private sector and on Capitol Hill. In industry, she provided organizational strategy and communications support to the S&T directorate and the Federal Emergency Management Agency where she authored the communications strategy for the multi-million dollar, multi-agency rollout of Presidential Policy Directive 8 (This directive is aimed at strengthening the security and resilience of the United States through systematic preparation for the threats that pose the greatest risk to the security of the Nation, including acts of terrorism, cyber attacks, pandemics, and catastrophic natural disasters.)
Stem cell therapies are showing huge promise in a lot of areas, but one application that has scientists particularly excited is in next-generation treatments for Parkinson’s disease. A team experimenting in this area has demonstrated how implanting carefully cultivated stem cells into rats can bring about remarkable recovery from motor symptoms typical of the disease, and are now setting their sights on upcoming human trials.
Parkinson’s disease is considered a prime target for innovative stem ell therapies because the condition can be traced back to the deterioration of a particular type of cell in a particular region of the brain. The neurons in the substantia nigra, a structure in the midbrain, are responsible for producing dopamine, which helps control movement, among other things.
The loss of these neurons is what contributes to motor symptoms in Parkinson’s patients, so using stem cell therapies to replace them is a very appealing idea, and one that has started to migrate from animal testing to humans. In a world-first trial undertaken in Japan in 2018, Parkinson’s patients had stem-cell-derived precursor cells implanted into their brains where they matured into the dopamine-producing neurons, with a number of subjects reported to be doing well.
A receptor that was first identified as necessary for insulin action, that also is located on the neural stem cells found deep in the brains of mice, is pivotal for brain stem cell longevity, according to a Rutgers study, a finding that has important implications for brain health and future therapies for brain disorders.
The study 0, appearing in the journal Stem Cell Reports, pinpoints a specific protein known as the insulin receptor (INSR), which is abundant on the neural stem cells that reside in the brain’s subventricular zone. During development, neural stem cells give rise to the entire nervous system, and they persist into adulthood. Over the lifespan these neural stem cells produce new neurons and non-neuronal cells that maintain the infrastructure and functioning of the brain.
Separately, the scientists made another finding when examining brain tumors: INSR plays a crucial role in sustaining and maintaining a population of specialized brain cancer cells known as glioblastoma (GBM) stem cells. When they inactivated the INSR in the GBM stem cells they inhibited the growth of those primitive tumor forming cells.
